16 Hrs
Source:
صحة
صحة
Ready to play
Ready to play
The U.S. Food and Drug Administration has warned of a possible association between GLP-1 drugs used for diabetes and weight loss—including Ozempic, Wegovy, Mounjaro, and Zepbound—and a rare condition that may cause sudden, permanent vision loss. However, the evidence has not established a causal link. An analysis of 126 trials involving 134,253 participants recorded 15 possible cases: 10 among people taking the drugs and 5 in comparison groups, corresponding to 6.4 versus 3.8 cases per 100,000 person-years. Medical authorities do not recommend stopping treatment automatically without symptoms or consulting a doctor, given the drugs’ benefits and the low absolute risk. But sudden vision loss—especially in one eye and without pain—requires urgent evaluation.
Notice: This Is an AI-Generated Summary
Comments (0)